¿Cuáles son los mecanismos de acción de la inmunoterapia en oncología?

Authors

  • Federico Cayol Sección Oncología. Servicio de Clínica Médica Hospital Italiano de Buenos Aires

DOI:

https://doi.org/10.51987/Rev.Hosp.Ital.B.Aires.v38i3.570

Downloads

Download data is not yet available.

References

Coley WB. The treatment of malignant tumors by repeated inoculations of erysipelas: with a report of ten original cases. Am J Med Sci. 1893; 105:487-511. DOI: https://doi.org/10.1097/00000441-189305000-00001

Finn OJ. Molecular Origins of Cancer Cancer Immunology. N Engl J Med 2008;358:2704-15. DOI: https://doi.org/10.1056/NEJMra072739

Oiseth SJ, Aziz MS. Cancer immunotherapy: a brief review of the history, possibilities, and challenges ahead. J Cancer Metastasis Treat.2017; 3:250-6. DOI: https://doi.org/10.20517/2394-4722.2017.41

Puzanov I, Diab A, Abdallah K, et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer. 2017; 5:95. DOI: https://doi.org/10.1186/s40425-017-0300-z

Shoushtari AN, Wolchok J, Hellman M. Principles of cancer immunotherapy. UptoDate 2018.

Downloads

Published

2018-09-30

Issue

Vol. 38 No. 3 (2018): Revista del Hospital Italiano de Buenos Aires

Section

Ask the expert

License

Copyright (c) 2018 Revista del Hospital Italiano de Buenos Aires

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

How to Cite

1.
Cayol F. ¿Cuáles son los mecanismos de acción de la inmunoterapia en oncología? Rev Hosp Ital B.Aires [Internet]. 2018 Sep. 30 [cited 2026 Aug. 21];38(3):123-5. Available from: https://ojs.hospitalitaliano.org.ar/index.php/revistahi/article/view/570